U.S. Lysosomal Storage Disease Treatment Market (2025 - 2033) Size, Share & Trends Analysis Report By Type (Enzyme Replacement Therapy (ERT)), By Disease Type, By Country, And Segment Forecasts
- Report Summary
- Table of Contents
- Segmentation
- Methodology
- Download FREE Sample
-
Download Sample Report
Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Disease Type
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. GVR’s Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. U.S. Lysosomal Storage Disease (LSDs) Treatment Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. U.S. Lysosomal Storage Disease (LSDs) Treatment Market: Type Business Analysis
4.1. Type Market Share, 2024 & 2033
4.2. Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Billion)
4.4. Enzyme Replacement Therapy (ERT)
4.4.1. Enzyme Replacement Therapy (ERT) Market, 2021 - 2033 (USD Billion)
4.4.2. Imiglucerase (Cerezyme)
4.4.2.1. Imiglucerase (Cerezyme) Market, 2021 - 2033 (USD Billion)
4.4.3. Alglucosidase alfa (Myozyme/Lumizyme)
4.4.3.1. Alglucosidase alfa (Myozyme/Lumizyme) Market, 2021 - 2033 (USD Billion)
4.4.4. Idursulfase (Elaprase)
4.4.4.1. Idursulfase (Elaprase) Market, 2021 - 2033 (USD Billion)
4.4.5. Velaglucerase alfa
4.4.5.1. Velaglucerase alfa Market, 2021 - 2033 (USD Billion)
4.4.6. Others
4.4.6.1. Others Market, 2021 - 2033 (USD Billion)
4.5. Substrate Reduction Therapy (SRT)
4.5.1. Substrate Reduction Therapy (SRT) Market, 2021 - 2033 (USD Billion)
4.6. Other Types
4.6.1. Other Types Market, 2021 - 2033 (USD Billion)
Chapter 5. U.S. Lysosomal Storage Disease (LSDs) Treatment Market: Disease Type Business Analysis
5.1. Disease Type Market Share, 2024 & 2033
5.2. Disease Type Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Disease Type, 2021 to 2033 (USD Billion)
5.4. Gaucher Disease
5.4.1. Gaucher Disease Market, 2021 - 2033 (USD Billion)
5.5. Fabry Disease
5.5.1. Fabry Disease Market, 2021 - 2033 (USD Billion)
5.6. Pompe Disease
5.6.1. Pompe Disease Market, 2021 - 2033 (USD Billion)
5.7. Mucopolysaccharidoses (MPS)
5.7.1. Mucopolysaccharidoses (MPS) Market, 2021 - 2033 (USD Billion)
5.8. Others
5.8.1. Others Market, 2021 - 2033 (USD Billion)
Chapter 6. Competitive Landscape
6.1. Participant Overview
6.2. Company Market Position Analysis
6.3. Company Categorization
6.4. Strategy Mapping
6.5. Company Profiles/Listing
6.5.1. Pfizer Inc
6.5.1.1. Overview
6.5.1.2. Financial Performance
6.5.1.3. Type Benchmarking
6.5.1.4. Strategic Initiatives
6.5.2. Takeda Pharmaceutical Company Limited (Shire Plc)
6.5.2.1. Overview
6.5.2.2. Financial Performance
6.5.2.3. Type Benchmarking
6.5.2.4. Strategic Initiatives
6.5.3. Sanofi (Genzyme Corporation)
6.5.3.1. Overview
6.5.3.2. Financial Performance
6.5.3.3. Type Benchmarking
6.5.3.4. Strategic Initiatives
6.5.4. BioMarin
6.5.4.1. Overview
6.5.4.2. Financial Performance
6.5.4.3. Type Benchmarking
6.5.4.4. Strategic Initiatives
6.5.5. Johnson & Johnson (Actelion Pharmaceuticals Ltd)
6.5.5.1. Overview
6.5.5.2. Financial Performance
6.5.5.3. Type Benchmarking
6.5.5.4. Strategic Initiatives
6.5.6. Amicus Therapeutics, Inc
6.5.6.1. Overview
6.5.6.2. Financial Performance
6.5.6.3. Type Benchmarking
6.5.6.4. Strategic Initiatives
6.5.7. Alexion Pharmaceuticals, Inc
6.5.7.1. Overview
6.5.7.2. Financial Performance
6.5.7.3. Type Benchmarking
6.5.7.4. Strategic Initiatives
6.5.8. Sigilon Therapeutics, Inc
6.5.8.1. Overview
6.5.8.2. Financial Performance
6.5.8.3. Type Benchmarking
6.5.8.4. Strategic Initiatives
6.5.9. Orphazyme A/S
6.5.9.1. Overview
6.5.9.2. Financial Performance
6.5.9.3. Type Benchmarking
6.5.9.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 U.S. lysosomal storage disease (LSDs) treatment market, by type, 2021 - 2033 (USD Billion)
Table 4 U.S. lysosomal storage disease (LSDs) treatment market, by disease type, 2021 - 2033 (USD Billion)
List of Figures
Fig. 1 U.S. lysosomal storage disease (LSDs) treatment market segmentation
Fig. 2 Market research process
Fig. 3 Data triangulation techniques
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Market snapshot
Fig. 9 Competitive landscape
Fig. 10 U.S. lysosomal storage disease (LSDs) treatment market dynamics
Fig. 11 U.S. lysosomal storage disease (LSDs) treatment market: Porter’s five forces analysis
Fig. 12 U.S. lysosomal storage disease (LSDs) treatment market: PESTLE analysis
Fig. 13 Type market, 2021 - 2033 (USD Billion)
Fig. 14 Enzyme replacement therapy market, 2021 - 2033 (USD Billion)
Fig. 15 Imiglucerase (Cerezyme) market, 2021 - 2033 (USD Billion)
Fig. 16 Alglucosidase alfa (Myozyme/Lumizyme) market, 2021 - 2033 (USD Billion)
Fig. 17 Idursulfase (Elaprase) market, 2021 - 2033 (USD Billion)
Fig. 18 Velaglucerase alfa market, 2021 - 2033 (USD Billion)
Fig. 19 Others market, 2021 - 2033 (USD Billion)
Fig. 20 Substrate reduction therapy market, 2021 - 2033 (USD Billion)
Fig. 21 Other types market, 2021 - 2033 (USD Billion)
Fig. 22 Disease type market, 2021 - 2033 (USD Billion)
Fig. 23 Gaucher disease market, 2021 - 2033 (USD Billion)
Fig. 24 Fabry disease market, 2021 - 2033 (USD Billion)
Fig. 25 Pompe disease market, 2021 - 2033 (USD Billion)
Fig. 26 Mucopolysaccharidoses market, 2021 - 2033 (USD Billion)
Fig. 27 Others market, 2021 - 2033 (USD Billion)
Fig. 28 Company categorization
Fig. 29 Company market position analysis
Fig. 30 Strategic framework
Get Free Sample Report
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
Trusted market insights - try a free sample
See how our reports are structured and why industry leaders rely on Grand View Research. Get a free sample or ask us to tailor this report to your needs.
